Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright lowered their price target on shares of Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating for the company in a research report on Thursday, May 2nd.

Minerva Neurosciences Stock Performance

Shares of NASDAQ:NERV opened at $2.44 on Friday. The firm has a market capitalization of $17.07 million, a P/E ratio of -0.55 and a beta of 0.27. The stock has a 50 day moving average price of $2.51 and a 200-day moving average price of $5.04. Minerva Neurosciences has a 52-week low of $2.29 and a 52-week high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.07. On average, equities analysts forecast that Minerva Neurosciences will post -1.89 EPS for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.